摘要
本文对抗肿瘤药物肝损伤的危险因素、诊断标准和临床分型、特异性易感基因检测的研究现状进行归纳,同时结合自身研究成果,总结抗肿瘤药肝损伤的防治措施,提出建设抗肿瘤药物肝损伤分子检测与临床评价技术平台,将对预测药物肝损伤的发生、指导临床化疗药物使用和新型药物开发具有重要的意义。
This review focused on the current understanding of anti-tumor drugs induced liver injury（DILI）, and analyzed the risk factors of DILI, clinical diagnosis criterion, classification of DILI and the potential specific genes for DILI by review of the current literatures. Based on our own research results, the prevention and control measures for DILI in anti-tumor treatment were summarized. And building up the molecule test and clinical evaluation technical platform for antitumor drugs induced liver injury will be critical for predicting DILI, directing rational use of anti-tumor drugs and new drug development.
出处
《中国药物应用与监测》
CAS
2012年第6期309-313,共5页
Chinese Journal of Drug Application and Monitoring
基金
国家十二五新药创制重大专项课题资助项目(2011ZX09302-001-02)
关键词
抗肿瘤治疗
药物性肝损伤
Anti-tumor treatment
Drug induced liver injury
